CRISPR Gene-Editing trial seeks to supercharge immune cells against incurable blood cancer
NCT ID NCT07340853
Summary
This early-stage trial is testing the safety and best dose of a new cell therapy for multiple myeloma that has returned or stopped responding to other treatments. Doctors take a patient's own immune cells, use CRISPR gene-editing technology to reprogram them to hunt down cancer cells, and then infuse them back into the patient. The main goal is to see if this personalized treatment is safe and tolerable for people with this advanced form of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.